Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Sellas Life Sciences Group Inc (SLS)

NASDAQ
Currency in USD
Disclaimer
1.330
-0.020(-1.48%)
Closed
After Hours
1.320-0.010(-0.752%)

SLS Comments

will go up now to 2.4🚀🚀🚀
gains
cannot see it on its chart
To clarify, this is a report for alignant pleural mesothelioma (MPM). which is in the first stageThe report for Acute Myeloid Leukemia (AML) which is in the third phase is coming out by the end of June. you have to wait, for now everything is ok
Updated Data Show Median Overall Survival of 35.4 Weeks in Patients Treated With Combination Therapy for at Least One Month – Median Overall Survival in Relapse/Refractory Patients with Standard of Care is Approximately 28 weeksNew and Updated Clinical and Translational Data Expected by End of Q4 2021NEW YORK, June 24, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced encouraging updated clinical data from a Phase 1 investigator-sponsored clinical trial of its lead clinical candidate, galinpepimut-S (GPS), combined with the checkpoint inhibitor nivolumab (Opdivo®) in patients with macroscopic (measurable) deposits of malignant pleural mesothelioma (MPM).
very good test results
👍👍
soon going to 30-50
Russel microcap index add.... Good...
Been in this from $2 21000shares I believe life changer
oll
https://www.sellaslifesciences.com/investors/news/News-Details/2021/SELLAS-Life-Sciences-Announces-USPTO-Decision-to-Grant-New-Patent-for-Galinpepimut-S-in-Combination-with-Checkpoint-Inhibitor-Therapies/default.aspx
https://www.sellaslifesciences.com/investors/news/News-Details/2021/SELLAS-Life-Sciences-Announces-USPTO-Decision-to-Grant-New-Patent-for-Galinpepimut-S-in-Combination-with-Checkpoint-Inhibitor-Therapies/default.aspx
Good stock
https://www.sellaslifesciences.com/investors/news/News-Details/2021/SELLAS-Life-Sciences-Reports-First-Quarter-2021-Financial-Results-and-Provides-Business-Update/default.aspx
https://www.tipranks.com/stocks/sls/dividends
https://seekingalpha.com/pr/18243773-sellas-life-sciences-reports-full-year-2020-financial-results-and-provides-business-update
o
https://finance.yahoo.com/news/sellas-life-sciences-reports-full-202100515.html
absolutly 2021 years in 20$. cancer and big money much potentially.. (china money..haha)
Hi, all, anyone got news? Should go over 10 today?
Price target next 6-9 month?
buy
big moment from Funding to bio FDA .
Go West~~~Life is peaceful there :) it will move soon. pls fasten your seatbelt.
Great stock with huge upside potential. $7 DO and 30+ million in cash to take GPS through FDA approval
Good news! https://www.bloomberg.com/press-releases/2020-12-21/sellas-announces-promising-initial-clinical-data-for-galinpepimut-s-gps-in-combination-with-checkpoint-inhibitors-in-two-solid
how do you think it's going to do? thinking about investing into it. been doing some research on it.
how do you think it's going to do? thinking about investing into it. been doing some research on it.
Right now it's been manipulated with naked shorts. I can't proof it but just look at the chart after it hit 19. But the fundamentals for the company is great 👍🏽.
...
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.